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Background: Under-prescription of antidepressants (ADs) among people meeting the criteria for major depressive
episodes and excessive prescription in less symptomatic patients have been reported. The reasons influencing
general practitioners’ (GPs) prescription of ADs remain little explored. This study aimed at assessing the influence of
GP and patient characteristics on AD prescription.
Methods: This cross-sectional study was based on a sample of 816 GPs working within the main health care insurance
system in the Seine-Maritime district of France during 2010. Only GPs meeting the criteria for full-time GP practice were
included. The ratio of AD prescription to overall prescription volume, a relative measure of AD prescription level, was
calculated for each GP, using the defined daily dose (DDD) concept. Associations of this AD prescription ratio with GPs’
age, gender, practice location, number of years of practice, number of days of sickness certificates prescribed, number
of home visits and consultations, number and mean age of registered patients, mean patient income, and number of
patients with a chronic condition were assessed using univariate and multivariate analysis.
Results: The high prescribers were middle-aged (40–59) urban GPs, with a moderate number of consultations and
fewer low-income and chronic patients. GPs’ workload (e.g., volume of prescribed drug reimbursement and number of
consultations) had no influence on the AD prescription ratio. GPs with more patients with risk factors for depression
prescribed fewer ADs, however, which could suggest the medications were under-prescribed among the at-risk
population.
Conclusions: Our study described a profile of the typical higher AD prescriber that did not include heavy workload. In
future work, a more detailed assessment of all biopsychosocial components of the consultation and other influences
on GP behavior such as prior training would be useful to explain AD prescription in GP’s practice.
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Antidepressants (ADs) are increasingly prescribed and
used worldwide, especially in all industrialized countries.
In the USA, Medicaid programs’ spending on antidepres-
sants increased from $159 million in 1991 to $2 billion in
2005 [1] and reached $9.6 billion in 2008 [2]. AD pre-
scription in France increased sixfold, from € 84 million* Correspondence: alain.mercier@univ-rouen.fr
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unless otherwise stated.to € 525 million, between 1980 and 2005 [3]. This high
AD prescription level, mainly coming from primary
care, is a source of concern. With the exception of use for
severe major depressive episodes, there is scarce evidence
on the effectiveness of AD use by physicians in primary
care [4]. The question of whether their prescription is
appropriate or not is a subject of debate. Some data
showed excessive prescription in patients with symptoms
not meeting all diagnostic criteria, yet misdiagnosis can
lead to under-prescription among truly depressed people
[5,6]. Many reports support the finding of an increasing
rate of non-psychiatric AD prescriptions [7-10]. The. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart of data extraction. Among the physicians
recorded as GPs, 17 were recorded with an exclusive particular
mode of practice (e.g. acupuncture), 13 did not prescribe any sick
leave, 24 had no chronic patients, 42 had no low-income patients, 4
had no conventional agreement with the health care system, 156
performed less than one consultation per day, and 16 had less than
two registered patients.
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tion for non-psychiatric conditions could also explain this
apparently inadequate prescription rate [11,12]. Though
high psychotropic drug consumption in some countries
such as France could be related to higher prevalence of
depression or to overall high drug consumption, the
available data do not allow reliable comparisons between
countries [13,14].
There is no consensus on the appropriateness of AD
prescription by general practitioners (GPs). The criteria
for defining “an appropriate prescription” for a given
indication differ among authors, and their assessment is
prone to variations in measurement, heavily influencing
findings on assessment of the rate of inadequate prescrip-
tions. Across all countries, GPs are responsible for 80% of
AD prescriptions [15]. AD prescription rates and habits
vary greatly among GPs [16]. “High” prescribers might
deal with patients having more comorbidities and more
risk factors for depression, such as age, the presence of a
chronic disease, and a low income level, but the findings
on these points are not consistent [9,17]. GPs’ prescription
of ADs might also be influenced by their demographic
characteristics (e.g., age, gender, and place of practice)
or profile of care (e.g., overall prescription volume and
number of patients in their practice) [18]. The aim of
this cross-sectional study was therefore to analyze the
influence of patient characteristics and GP demographic
characteristics and care profile on AD prescription based
on data from GP practices in France in 2010.
Methods
Study population
This cross-sectional study was based on the analysis of
characteristics and prescription data of a GP sample from
the Seine-Maritime district in northwestern France during
the year 2010. In 2010, this area had a population of
1,248,443 inhabitants and had 1,040 registered GPs. Re-
corded data from the main local health insurance system
(CNAM-TS) were used. All data on drug prescriptions
and characteristics of physicians and patients are routinely
collected in this database each time a patient asks for
prescribed drug reimbursement. Collected data are thus
rather exhaustive and reliable.
Among the 1,046 registered GPs, data from 36 GPs
were missing, thus leaving data for 1,004 registered GPs
for further selection. As our aim was to analyze data
coming from full-time standard primary GP practice, the
following exclusion criteria were applied to the initial
data sample of physicians registered as GPs. “Specialized”
physicians with a predominant particular mode of practice
(PMP) such as osteopathy or acupuncture, as well as those
practicing homeopathy or nutrition exclusively, were ex-
cluded. Other exclusion criteria were prescription of no or
only a few medications, no sickness certificates prescribed,performing no home visits, and having only a part-time
GP activity (e.g., a GP practice combined with hospital or
emergency department practices). GPs performing less
than one reimbursed consultation per day, and having no
contractual agreement with the French national health
insurance system, were also excluded. GPs were also
excluded when they did not treat chronic patients (i.e., no
patients with any of the 30 chronic diseases allowing
patients to be treated free of charge in France) or any very
low-income patients (i.e., no patients who can see a GP
free of charge based on their very low-income level as de-
fined by French law). After applying these criteria, the data
for 816 GPs were retained and constituted the analysis
sample. The different steps of data selection are presented
in Figure 1.
Agreement of the French National Commission for Data
Protection (Commission Nationale de l’Informatique et
des Libertés) was obtained (Decision DE 2010 097).
Data
The first set of variables described GP’s practice, i.e., the
GP’s age and gender, practice location (urban or rural
based on the postal code and on the National Institute of
Statistics and Economic Studies’ (INSEE) classification),
the year when they began practicing medicine, and the
part-time or full-time nature of their work. The second set
of variables described medical activity during the entire
year of 2010, i.e., the number of sick leave days prescribed
per year, the number of home visits and consultations, the
number of registered patients, the mean patient age, the
number of very low-income patients (“free of charge” pa-
tients), and the number of patients with a registered
chronic condition. The final set of variables described the
prescription activity for the entire year of 2010, i.e., the
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drug prescribed for all active ingredients, as a whole, and
detailed data for each AD molecule (The list of ADs in-
cluded is available in Additional file 1).
Assessment of the AD prescription ratio
As there is no universally recognized measure of AD
prescription level, an AD prescription ratio was defined
using the following steps. For each GP, yearly prescription
volumes of individual AD medications were converted
into defined daily dose (DDD) units and subsequently
pooled across all ADs to obtain the overall yearly AD pre-
scription level. The AD prescription ratio was obtained by
dividing this yearly AD prescription level by the overall
volume of prescribed units for all reimbursed medications.
Thus, the AD prescription ratio quantified the level of AD
prescription in relative terms. This variable was analyzed
both as a continuous variable and as a dichotomous vari-
able, using the median as the threshold to define higher
and lower prescribers.
Statistical methods
The analysis explored the influence of all characteristics
of GPs and their patients on the AD prescription ratio.
We first analyzed the AD prescription ratio as a continu-
ous variable. Univariate analyses relied on parametric (i.e.,
Student’s t-test or one-way ANOVA) or non-parametric
(i.e., Mann-Whitney’s non-parametric test or Kruskal-Wallis
test) methods depending on the distribution of the charac-
teristic considered. Variables separately associated with
the AD prescription ratio at the 0.05 level were retained
for multivariate analysis. In multivariate analysis, variables
independently associated with the AD prescription ratio at
the 0.05 level were determined using multiple linear re-
gression and backward stepwise selection. Second, the AD
prescription ratio was analyzed as a dichotomous variable
(see above), and the same general approach was used with
appropriate methods. Namely, univariate analysis relied
on Pearson’s chi-square test or Fisher’s exact test as appro-
priate and multivariate analysis relied on logistic regres-
sion and backward stepwise selection. Softwares Epi-info
(version 3.5.3) and SAS (version 9.2, SAS Institute, Cary,
North Carolina) were used.
Results
Description of the sample
The 816 GPs included in the study had a mean age of
52.7 years. Overall, they performed 5,186,461 consulta-
tions in a population of 1,248,443 inhabitants in 2010.
On average, they saw a mean of 1,059 different patients
over the year and performed 3,922 consultations and
home visits. The overall density and medical activity of
the GPs included in the study was similar to that for
France as a whole. In 2010, there were 53,422 physiciansregistered as GPs in France, which has a population of
65 million. GPs in France had a mean of 4,319 consulta-
tions or home visits in 2010 [19,20].
Characteristics of the AD prescription ratio
The mean and median numbers of prescribed boxes
(packaging sets) of all drugs were, respectively, 27,406
(standard deviation 15,972) and 26,421 (range 149 to
107,878). The mean and median numbers of prescribed
ADs were, respectively, 12,005 DDD (standard deviation
7,841) and 11,019 (range 4 to 50,594). The mean and
median AD prescription ratios were, respectively 0.45
(standard deviation 0.25) and 0.42 (range 0.004–4.00).
The AD prescription ratio had a roughly symmetric dis-
tribution in the range 0–1 with a small peak for very
low values (24 values were less than 0.1) and a few high
values (4 values were more than 2) (Figure 2).
Characteristics of GPs and their patients (Table 1)
Among the 816 GPs, 234 (28.7%) were female and 582
male (71.3%). The less common category of GP’s age was
the youngest (i.e., <40 years) age category (n = 72, 8.8%)
and the most frequent was the 50–59-year category of age
(n = 345, 42.3%). Overall, 190 GPs (23.3%) practiced in
rural areas. On average, GPs had 716 registered patients
with mean age 46 years and took care of 53 low-income
patients and 145 patients with a registered chronic condi-
tion allowing for full coverage of medical expenses by
their health insurance.
Predictors of AD prescription—univariate analysis (Table 2)
The AD prescription ratio as a continuous variable was
statistically significantly higher in relation with greater
GP’s age (p = 0.008), urban location (p = 0.01), larger over-
all volume of reimbursement (p < 0.001), larger number of
registered patients (p = 0.02), higher prescription of new
ADs (p = 0.001), larger number of patients being pre-
scribed sickness certificate days (p = 0.001), higher overall
volume of reimbursement (p = 0.01), larger number of
different patients seen per year (p = 0.001), larger overall
number of patients seen (p = 0.04), larger number of low-
income patients (p = 0.006), and larger number of patients
with a chronic disease (p = 0.02).
After dichotomizing the AD prescription ratio, physi-
cians between 40 and 59 years of age prescribed more
ADs compared to younger ones. Physicians working in
urban areas were higher AD prescribers than those
working in rural areas. Those with more than 500 regis-
tered patients were higher AD prescribers than those
with fewer registered patients. A higher number of sick-
ness certificates were associated with a higher AD pre-
scription rate. GPs prescribing new ADs frequently (>70%
of all ADs prescribed) were also higher AD prescribers.
Figure 2 Distribution of the ratio of AD prescription among the 816 GPs.
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fewer ADs.
Predictors of AD prescription—multivariate analysis
(Table 3)
In multivariate analysis, upon considering the AD pre-
scription ratio as continuous, the factors independently
showing a positive association with higher AD prescrip-
tion were intermediate GP’s age (40 to 59 years) and urban
practice location, whereas younger GP’s age (<40 years)
was associated with lower AD prescription. For instance,
GPs with a practice in an urban area had a higher AD pre-
scription ratio than GPs practicing in rural areas, with a
mean difference of 0.056 (95% confidence interval 0.016
to 0.096). Regarding prescription and overall activity,
higher total volume of drugs reimbursed and higher num-
ber of consultations and home visits were independently
associated with lower AD prescription (i.e., inverse associ-
ation). Finally, GPs prescribing new ADs more frequently
were also higher AD prescribers.
Upon considering the AD prescription ratio as dichot-
omous, analogous results were obtained for GP’s age
and practice location. For instance, the odds ratio of
higher AD prescription was 1.95 (95% confidence inter-
val 1.36 to 2.80) for GPs practicing in an urban area
relative to GPs practicing in a rural area. A higher
number of low-income patients in the practice were in-
versely associated with AD prescription. Regarding
prescription and overall activity, number of consulta-
tions and number of sick leave days prescribed were in-
versely associated with AD prescription. Finally, GPsprescribing new ADs more frequently were again higher
AD prescribers.
Discussion
From this study, it appears that the profile of the
“higher” prescriber was an urban, middle-aged GP
(40–59 years of age), prescribing a higher proportion
of new ADs and seeing fewer low-income patients.
Moreover, lower medical activity might be added to
this typical profile since the variables related to med-
ical activity (i.e., overall volume of reimbursement,
number of prescriptions per year, number of different
patients seen per year, number of consultations and
home visits, number of sick leave days prescribed) tended
to be inversely associated with AD prescription. This sug-
gests that GPs might have different prescription patterns
depending on their practice burden.
Some data showed that women practiced differently
and tended to take social problems more into account
[21]. In our study, however, there was no gender effect.
The main indications for prescribing ADs are depres-
sion and psychological problems [22]. France has the
highest proportion of patients taking ADs in Europe, but
because of shorter periods of use, France finished only in
the middle of the pack in a ranking of European countries
for total AD prescriptions [23]. Possible over-prescription
of ADs as well as a “drug prescription culture” has been
highlighted in France [24]. The figures from our study
seem to contradict the idea that high workload is related
to over-prescription of ADs, due to incorrect assessment
of patients.
Table 1 Characteristics of the study sample (n = 816)
Low prescribers (n = 408) High prescribers (n = 408)
Number Percent [95% confidence
interval]
Number Percent [95% confidence
interval]
Gender Female 116 28.4 [24.2–33.1] 118 28.9 [24.6–33.6]
Male 292 71.6 [66.9–75.8] 290 71.1 [66.4–75.4]
Practice location Rural 110 27.0 [22.8–31.6] 80 19.6 [15.9–23.9]
Urban 298 73.0 [68.4–77.2] 328 80.4 [76.1–84.0]
GP partially particular mode of practice Yes 40 9.8 [7.2–13.2] 13 3.2 [1.8–5.5]
No 368 90.2 [86.9–92.9] 395 96.8 [94.5–98.2]
Cessation of activity during the year 2010 Yes 7 1.7 [0.8–3.7] 7 1.7 [0.8–3.7]
No 401 98.3 [96.3–99.2] 401 98.3 [96.3–99.2]
Mean [Standard deviation] Mean [Standard deviation]
Age of GPs 52.6 [9.39] 52.8 [8.10]
Cumulative years of medical practice 19.83 [10.71] 20.5 [9.7146]
Number of consultations and home visits 3,982 [1,994] 3,863 [1,758]
Number of different patients per year 1,106 [538] 1,012 [396]
Number of registered patients 701 [406] 732 [346]
Mean age of patients 46.3 [6.02] 45 [6.1]
Number of patients with low income 60 [79] 45 [48]
Number of patients with chronic disease 145 [91] 144 [80]
Number of days of Sickness certificates prescribed 3,608 [2,537] 3,571 [2,225]
Number of patients prescribed a sickness certificate 100 [64] 94 [50]
Total volume of reimbursement (number of units) 28,247 [17,316] 26,565 [14,477]
Number of prescriptions orders 3,847 [2,122] 3,808 [1,859]
%≥ 70 new AD 0.86 [0.34] 0.95 [0.20]
Number of DDD 9,163 [6298] 14,848 [8,200]
AD prescription ratio 0.30 [0.09] 0.60 [0.27]
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No a priori sample size calculations were performed, but
our study was conducted on a large sample, so that
statistical power was high. Only the database of the
CNAM-TS was used in this study but this represents
80% of the population. Moreover, after having applied
selection criteria, our sample was almost exhaustive. The
average number of consultations per GP in our sample
(n = 3,922) was close to that in French GPs (n = 4,319).
The influence of PMPs in the univariate analysis under-
lines the fact that excluding those who had a large share
of partial PMPs was relevant.
In the absence of a universally recognized measure of
AD prescription level, the AD prescription ratio was de-
vised for this study. We chose a relative measure of AD
prescription in order to eliminate the influence of overall
prescription level. Moreover, the numerator was expressed
in DDD in order to have an accurate quantification of AD
prescription. It was not possible to express the denomin-
ator in terms of DDD as well since the CNAM-TSdatabase used in this analysis does not include infor-
mation on indication. Thus, for medications with several
possible indications (e.g., non-steroidal anti-inflammatory
drugs or pain killers), a unique DDD calculation was not
possible. This is why the denominator was expressed in
terms of medication units, yielding a hybrid ratio. Alterna-
tively, an absolute measure of AD prescription could have
been used. For instance, using the same numerator but
using the number of patients seen in the year 2010 as
the denominator would yield a rate of AD prescription
per patient. This absolute AD prescription rate and our
AD prescription ratio have different (albeit correlated)
denominators and do not capture the same AD pre-
scription features. For instance, a low AD prescription
rate may correspond to either a low AD prescription ratio
if the GP is a low AD prescriber but an average-to-high
drug prescriber overall or a high AD prescription ratio if
the GP is a low drug prescriber overall and an even lower
AD prescriber, two very different situations that can be
distinguished upon using the AD prescription ratio but
Table 2 Characteristics of the study sample (n = 816) and results of univariate analysis for the AD prescription ratio as
a continuous variable and as a dichotomous variable (<0.42 for “low” prescribers and ≥0.42 for “high” prescribers)




Characteristics of the GPs
Gender Female 234 28.7 0.47 [0.22] 1
Male 582 71.3 0.44 [0.26] 0.98 (0,84;1.15)
Age category <40 years 72 8.8 0.39 [0.15] 1
40 to 49 years 198 24.3 0.47 [0.21] 1.58 (1.26;1.96)
50 to 59 years 345 42.3 0.47 [0.24] 1.53 (1.26;1.86)
≥60 years 201 24.6 0.43 [0.31] 1.21 (0.99;1.47)
Practice location Rural 190 23.3 0.41 [0.16] 1
Urban 626 76.7 0.46 [0.27] 1.20 (1.05;1.4)
GP partially particular mode of practice Yes 53 6.5 0.39 [0.67] 0.63 (0.53; 0.7)
No 763 93.5 0.45 [0.19] 1
Cessation of activity during the year 2010 Yes 14 1.7 0.46 [0.21] 0.84 (0.45;1.54)
No 802 98.3 0.45 [0.25] 1
Cumulative years of medical practice <10 155 19 0.42 [0.19] 1
10–19 213 26.1 0.45 [0.20] 1.06 (0.87;1.30)
20–29 267 32.7 0.47 [0.23] 1.18 (0.97;1.44)
>30 181 22.2 0.46 [0.35] 1.04 (0.85;1.27)
Characteristics of the GP’s practice and patients in 2010
Number of consultations and home visits <1,999 113 13.8 0.51 [0.50] 1
2,000 to 3,999 320 39.2 0.45 [0.22] 1.00 (0.80;1.24)
4,000 to 5,999 296 36.3 0.44 [0.14] 1.03 (0.82;1.28)
≥6,000 87 10.7 0.40 [0.15] 0.81 (0.63;1.05)
Number of different patients per year <999 369 45.2 0.47 [0.31] 1
>1,000 447 54.8 0.43 [0.18] 0.90 (0.79;1.04)
Number of registered patients <499 213 26.1 0.46 [0.42] 1
500–1,000 435 53.3 0.45 [0.15] 1.21 (1.04;1.41)
>1,000 168 20.6 0.45 [0.15] 1.28 (1.05;1.57)
Mean age of patients <40 83 10.2 0.46 [0.37] 1
40–49 574 70.3 0.46 [0.20] 1.11 (0.89;1.38)
≥50 159 19.5 0.43 [0.34] 0.92 (0.72;1.18)
Number of patients with low income* <39 478 58.6 0.46 [0.30] 1
40–79 176 21.6 0.45 [0.16] 0.95 (0.80;1.14)
≥80 162 19.9 0.41 [0.14] 0.77 (0.66;0.90)
Number of patients with chronic diseasea <100 244 29.9 0.48 [0.40] 1
100–199 361 44.2 0.45 [0.14] 1.06 (0.86;1.25)
200–299 175 21.4 0.43 [0.14] 0.93 (0.77;1.12)
≥300 36 4.4 0.40 [0.10] 0.90 (0.66;1.24)
Number of days of sickness certificates prescribed <1,999 223 27.3 0.46 [0.42] 1
2,000–3,999 281 34.4 0.46 [0.14] 1.34 (1.12;1.60)
4,000–5,999 191 23.4 0.44 [0.15] 1.12 (0.93;1.38)
≥6,000 121 14.8 0.42 [0.14] 1.00 (0.82;1.22)
Number of patients prescribed a sickness certificate <100 454 55.6 0.46 [0.31] 1
≥100 362 44.4 0.44 [0.14] 0.97 (0.84;1.11)
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Table 2 Characteristics of the study sample (n = 816) and results of univariate analysis for the AD prescription ratio as
a continuous variable and as a dichotomous variable (<0.42 for “low” prescribers and ≥0.42 for “high” prescribers)
(Continued)
Prescription of new ADs ≥70% new AD 741 90.8 0.46 [0.25] 1.60 (1.38;1.86)
<70% new ADs 75 9.2 0.33 [0.17] 1
Total volume of reimbursement (number of units) 0–19,999 261 32 0.49 [0.39] 1
20,000–39,999 397 48.7 0.44 [0.14] 0.96 (0.82;1.13)
≥40,000 158 19.4 0.41 [0.15] 0.87 (0.75;1.01)
Number of prescriptions orders 0 to 1,999 152 18.6 0.49 [0.49] 1
2,000 to 3,999 298 36.5 0.45 [0.16] 1.11 (0.92;1.35)
4,000 to 5,999 270 29.9 0.44 [0.14] 1.08 (0.89;1.31)
≥6,000 96 9.7 0.42 [0.13] 0.98 (0.77;1.24)
*Patients with low income, treated free of charge, with no direct payment to the GP.
aChronic diseases, at least one of 30 chronic conditions such as type 2 diabetes, or chronic heart failure.
bAD prescription ratio as a continuous variable.
cRelative to the dichotomized AD prescription ratio using the lower prescription level as the reference level.
Table 3 Multivariate analysis: variables independently associated with the dichotomized AD prescription ratio
(<0.42 for lower prescribers and ≥0.42 for higher prescribers)
Variable Mean difference in AD prescription ratio [95% CI]b OR [95% CI]c
GP’s age
≥60 0 1
50–59 0.026 [−0.023; 0.074] 1.87 [1.29; 2.71]
40–49 0.038 [−0.049; 0.080] 1.74 [1.14; 2.64]
<40 −0.068 [−0.14; 0.00] 0.65 [0.35; 1.2]
Practice location:
Rural 0 1
Urban 0.056 [0.016; 0.096] 1.954 [1.3; −2.80]
Number of consultations/year/GP* 0.93a [0.90–0.97]
Number of patients with low income
≥80 1
40–79 1.69 [1.06; 2.67]
<39 2.23 [1.45; 3.40]
Class of prescription
<70% new ADs 0 1
>70% new ADs 0.12 [0.058; 0.18] 3.45 [1.94; 6.15]
Cumulative number of sick leave days prescribed per year
≥6,000 1
4,000–5,999 0.91 [0.55; 1.47]
2,000–3,999 1.12 [0.68; 1.84]
Fewer than 1,999 0.43 [0.24; 0.78]
Total volume of drugs reimbursed −0.0053* [−0.0084; −0.00233]
Total volume of prescription orders 0.0462** [0.0184; 0.0740]
Number of consultations and home visits −0.0128*** [−0.0179; −0.0077]
*Mean difference per 1,000 additional drugs reimbursed (quantitative variable).
**Mean difference per 1,000 additional prescription orders (quantitative variable).
***Mean difference per 100 additional consultations or home visits.
aOdds ratio per 100 additional consultations (quantitative variable).
bFrom multiple linear regression applied to the AD prescription ratio as a continuous variable.
cFrom multiple logistic regression applied to the dichotomized AD prescription ratio using the lower prescription level as the reference level.
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ent with the AD prescription rate compared to those ob-
tained with the AD prescription ratio, and our results
have to be interpreted with this element of caution in
mind.
Since only variables present in the database were used,
it is possible that important determinants of AD prescrip-
tion were missed such as detailed individual patient char-
acteristics. Our study relied on an overall assessment of
GPs’AD prescriptions. We do not have figures on referral
for diagnosis and treatment. A prescription renewed by a
GP could have initially come from secondary care.
As well, AD prescription is a proxy to identify depression
and psychological distress, but ADs are also prescribed for
non-psychiatric reasons, though the exact proportion of
this phenomenon is unknown [10,25,26]. This impacts the
relevance of our conclusions on GP behavior. Finally, our
study did not address the overall usefulness and appropri-
ateness of prescriptions since the database that we used
does not include indications. This also means that re-
searchers and policymakers need to interpret prescription
levels in a careful manner.
Hypotheses and further implications
Middle-aged GPs (40–59 years of age) seemed to pre-
scribe ADs more than younger or older GPs. However,
the number of years of practice, partially related to a
physician’s age, seemed to have no influence on AD pre-
scription. Prescribing “old” ADs was independently related
with a lower ratio of AD prescription. Rural GPs pre-
scribed ADs less than did urban practitioners. As data
on precise assessment of the patients’ conditions were
lacking, only hypotheses can be made: for example,
elderly patients are more likely to have an older GP
and to be depressed [25]. The sensitivity and odds of
diagnosis of depression by older non-psychiatric physi-
cians could be lower [26]. However, older GP’s age could
also be related to greater experience and a better under-
standing of the patient, thus avoiding over-prescription of
ADs. Differences between rural and urban areas may also
be explained by over-prescription in urban areas, but the
lack of higher AD prescriptions among “at risk” popula-
tions, such as low-income people, makes this explanation
less likely.
Due to differences in the sample characteristics, and
in the variables assessed, our data cannot be directly
compared with those of the study of Morrison on the
same subject [27]. Nevertheless, conclusions concerning
the association of urban practices with greater AD pre-
scription are similar. Conversely, our results do not
show any influence of risk factors for depression, which
may suggest a lack of diagnosis recognition, or other
prescriptions other than ADs, such as psychological
care. The conclusions on the influence of GP’s age arenot consistent with those of Morrison either, with the
oldest GPs prescribing less than middle-aged GPs in our
study. In either study, findings do not indicate whether
there is a lack of recognition of depression by older GPs
or a more easy prescription for moderate depression
among younger GPs.
Although chronic diseases and low income are well-
known risk factors for depression [25-28], only the latter
was found associated with increased AD prescription
with an inverse association in our study. Rural patients
received fewer AD prescriptions, although we know de-
pression also occurs in rural settings [28]. This might be
related to under-detection in this context. It is known that
all GPs tend to have difficulties in recognizing patients’
needs for mental care. Structural heath care system prob-
lems, such as difficulties in accessing mental health care
services, have already been pointed out [29-31]. Poor co-
ordination between secondary and primary care has also
been highlighted [30,32]. Better coordinated care could
improve prescription quality outcomes [33,34]. Enhancing
shared decisions and shared care has been shown to be ef-
fective [33,35]. AD prescriptions have to be assessed on
relevant outcomes such as increased prescription among
chronic patients with comorbidities and those who belong
from lower social classes.
To go further and understand individual GPs’ behavior
would require a more in-depth assessment of the pa-
tients’ situations including all biopsychosocial compo-
nents of the medical situation. But, we also know that
GPs AD prescription behavior relies on many personal
and contextual factors [36], such as adherence to the
guidelines, availability of psychotherapists, and beliefs
on ADs’ efficacy and effectiveness. Other influences
such as prior training or experience of prescribing
antidepressants also have to be taken into account in
future studies, to assess the way this impacts GPs’ pre-
scription strategies.
Conclusions
Our study found that the profile of the higher prescriber
was an urban, middle-aged GP (40–59 years of age)
more often prescribing recent ADs and having fewer
low-income patients. The total volume of reimburse-
ment and the volume of consultations did not increase
the prescription ratio. These findings do not support
the idea that workload is the cause of over-prescription
of ADs.
Further understanding would require analyzing both
the influence of patients’ situations and other GPs’ char-
acteristics, such as the use of guidelines, prior training,
or prior experience of prescribing ADs. In-depth assess-
ment of all biopsychosocial components of the medical
situation and other influences on GPs behavior would be
useful to better explain AD prescriptions.
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